Omrix Biopharmaceuticals, Inc.
630 5th Avenue
22nd Floor
New York
New York
10111
United States
Tel: 212-887-6500
Fax: 212-887-6550
Website: http://www.omrix.com/
Email: info@omrix.com
103 articles about Omrix Biopharmaceuticals, Inc.
-
Macrocure Taps Ex-Omrix Biopharmaceuticals, Inc. President, Nissim Mashiach as New President & CEO
6/13/2012
-
Johnson & Johnson Completes Omrix Biopharmaceuticals, Inc. Tender Offer
12/29/2008
-
Johnson & Johnson Extends Tender Offer for Omrix Biopharmaceuticals, Inc.
12/22/2008
-
Johnson & Johnson Announces Receipt of Israeli Antitrust Approval for Acquisition of Omrix Biopharmaceuticals, Inc.
12/12/2008
-
Johnson & Johnson (JOBS) Acquire Omrix Biopharmaceuticals, Inc. for $438 Million
11/24/2008
-
Omrix Biopharmaceuticals, Inc. Shares Gain Ground Monday On Buyout Speculation
11/11/2008
-
Omrix Biopharmaceuticals, Inc. Announces Third Quarter 2008 Financial Results
11/6/2008
-
Omrix Biopharmaceuticals, Inc. to Webcast Presentation at Rodman & Renshaw Annual Healthcare Conference
11/4/2008
-
Omrix Biopharmaceuticals, Inc. Reschedules its Third Quarter 2008 Financial Results and Conference Call to an Earlier Time on November 6, 2008
11/3/2008
-
Omrix Biopharmaceuticals, Inc. to Resume U.S. Trials of Anti-Bleeding Product
10/27/2008
-
Omrix Biopharmaceuticals, Inc. Announces Third Quarter 2008 Financial Results Date and Conference Call
10/21/2008
-
Omrix Biopharmaceuticals, Inc. Provides Preliminary Third Quarter 2008 Results and Increases 2008 Product Sales Guidance
10/20/2008
-
Omrix Biopharmaceuticals, Inc.'s Fibrin Pad U.S. Phase II Clinical Trial In Mild To Moderate Bleeding Was Suspended Yesterday Afternoon To Investigate An Incident Of Post-Operative Bleeding; Shares Down
10/9/2008
-
Omrix Biopharmaceuticals, Inc. Says Anti-Bleeding Product Shows Promise; Shares Rise
10/8/2008
-
Omrix Biopharmaceuticals, Inc. Announces Interim Analysis Indicating Superiority Of Fibrin Pad Versus SURGICEL In Mild To Moderate Bleeding In U.S. Phase II Clinical Trial And Provides Update On Additional Fibrin Pad Clinical Trials
10/8/2008
-
Omrix Biopharmaceuticals, Inc. Completes Enrollment of Initial 90 Patients Needed to Conduct Interim Analysis in Fibrin Pad U.S. Phase II Clinical Trial
9/22/2008
-
Omrix Biopharmaceuticals, Inc. to Webcast Presentation at UBS Warburg Global Life Sciences Conference
9/15/2008
-
Omrix Biopharmaceuticals, Inc. Shares Rise [Monday] On Speculation Over Buyout Offer
8/19/2008
-
Omrix Biopharmaceuticals, Inc. Appoints Asaf Alperovitz as Chief Financial Officer
8/12/2008
-
Omrix Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results
8/12/2008